Amedeo Smart

Free Medical Literature Service



Multiple Sclerosis

  Free Subscription

Articles published in
J Neurol Sci
    August 2022
  1. MERMELSTEIN M, Naftali J, Wilf-Yarkoni A, Lotan I, et al
    Repeated lumbar puncture in search of oligoclonal bands - What is the yield?
    J Neurol Sci. 2022;439:120298.
    >> Share

    July 2022
  2. HARIRCHIAN MH, Zahednasab H, Karampoor S
    The enigmatic role of macrophage inhibitory factor (MIF) in the pathogenesis of multiple sclerosis (MS).
    J Neurol Sci. 2022;440:120351.
    >> Share

  3. GENTILI L, Capuano R, Gaetani L, Fiacca A, et al
    Impact of post-contrast MRI in the definition of active multiple sclerosis.
    J Neurol Sci. 2022;440:120338.
    >> Share

    June 2022
  4. HJAERESEN S, Sejbaek T, Axelsson M, Mortensen SK, et al
    MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis.
    J Neurol Sci. 2022;439:120320.
    >> Share

  5. MOCCIA M, Buonomo AR, Scotto R, Viceconte G, et al
    Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series.
    J Neurol Sci. 2022;439:120306.
    >> Share

    May 2022
  6. LOREFICE L, Pilotto S, Fenu G, Cimino P, et al
    Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
    J Neurol Sci. 2022;438:120292.
    >> Share

    February 2022
  7. KATO S, Hagiwara A, Yokoyama K, Andica C, et al
    Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.
    J Neurol Sci. 2022;436:120205.
    >> Share

  8. YOUNG CA, Mills R, Langdon D, Sharrack B, et al
    The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
    J Neurol Sci. 2022;436:120188.
    >> Share

    January 2022
  9. DREYER-ALSTER S, Menascu S, Mandel M, Shirbint E, et al
    COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
    J Neurol Sci. 2022;434:120155.
    >> Share

  10. CHU L, Casserly C, Rosehart H, Morrow SA, et al
    Is there a multiple sclerosis personality? Personality characteristics in newly diagnosed multiple sclerosis and association with mood and cognition.
    J Neurol Sci. 2022;434:120145.
    >> Share

    November 2021
  11. MENASCU S, Fattal-Valevski A, Vaknin-Dembinsky A, Milo R, et al
    Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage.
    J Neurol Sci. 2021;432:120074.
    >> Share

  12. KENNEY R, Liu M, Patil S, Alroughani R, et al
    Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.
    J Neurol Sci. 2021;430:118067.
    >> Share

    October 2021
  13. BEARD K, Sriwastava S
    Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis.
    J Neurol Sci. 2021;430:120034.
    >> Share

  14. BRINGELAND GH, Blaser N, Myhr KM, Vedeler CA, et al
    Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic.
    J Neurol Sci. 2021;429:117622.
    >> Share

  15. SCOTT TF
    Neurosarcoidosis mimicry of MS: Clues from cases with CNS tissue diagnosis.
    J Neurol Sci. 2021;429:117621.
    >> Share

    September 2021
  16. PLOWMAN RS, Varma H
    Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
    J Neurol Sci. 2021;428:117591.
    >> Share

  17. XIE JS, Jeeva-Patel T, Margolin E
    Balo's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.
    J Neurol Sci. 2021;428:117570.
    >> Share

  18. CRISTIANO E, Abad P, Becker J, Carra A, et al
    Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation.
    J Neurol Sci. 2021;429:118072.
    >> Share

    August 2021
  19. RICE DR, Kaplan TB, Hotan GC, Vogel AC, et al
    Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
    J Neurol Sci. 2021;428:117612.
    >> Share

    July 2021
  20. VISSER LA, Huls SPI, Uyl-de Groot CA, de Bekker-Grob EW, et al
    An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
    J Neurol Sci. 2021;428:117587.
    >> Share

    June 2021
  21. VAN DER HIELE K, van Gorp DAM, van Egmond EEA, Jongen PJ, et al
    Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
    J Neurol Sci. 2021;427:117561.
    >> Share

  22. JAKIMOVSKI D, Zivadinov R, Vaughn CB, Ozel O, et al
    Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis.
    J Neurol Sci. 2021;427:117552.
    >> Share

  23. WIJERATNE T, Grisold W, Carroll W
    World Brain Day 2021 campaign continue to gain the momentum; join us to stop multiple sclerosis.
    J Neurol Sci. 2021;427:117547.
    >> Share

  24. FUJIMORI J, Nakashima I
    Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2021;427:117528.
    >> Share

    May 2021
  25. TAZZA F, Lapucci C, Cellerino M, Boffa G, et al
    Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    J Neurol Sci. 2021;427:117501.
    >> Share

  26. DE MERCANTI SF, Signori A, Cordioli C, Signoriello E, et al
    MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    J Neurol Sci. 2021;424:117385.
    >> Share

    April 2021
  27. YOUNG CA, Mills R, Rog D, Sharrack B, et al
    Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
    J Neurol Sci. 2021;426:117437.
    >> Share

  28. ALLUM JHJ, Rust HM, Lutz N, Schouenborg C, et al
    Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.
    J Neurol Sci. 2021;425:117432.
    >> Share

    March 2021
  29. FERRARO D, Annovazzi P, Lanzillo R, Calabrese M, et al
    A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.
    J Neurol Sci. 2021;424:117430.
    >> Share

    February 2021
  30. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
    Early neuropsychological markers of cognitive involvement in multiple sclerosis.
    J Neurol Sci. 2021;423:117349.
    >> Share

    January 2021
  31. BOSE G, Freedman MS
    Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    J Neurol Sci. 2021;421:117324.
    >> Share

  32. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    >> Share

    December 2020
  33. WEBER J, Bernsdorff N, Robinson T, Endres D, et al
    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    J Neurol Sci. 2020;421:117289.
    >> Share

    October 2020
  34. VARMA-DOYLE AV, Lukiw WJ, Zhao Y, Lovera J, et al
    A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.
    J Neurol Sci. 2020 Oct 23:117202. doi: 10.1016/j.jns.2020.117202.
    >> Share

  35. BARREIRO-GONZALEZ A, Sanz MT, Carratala-Bosca S, Perez-Miralles F, et al
    Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
    J Neurol Sci. 2020;419:117180.
    >> Share

    September 2020
  36. ILARDI M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, et al
    Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.
    J Neurol Sci. 2020;419:117159.
    >> Share

  37. CHAUDHRY F, Bulka H, Rathnam AS, Said OM, et al
    COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    J Neurol Sci. 2020;418:117147.
    >> Share

  38. JAKIMOVSKI D, Zivadinov R, Dwyer MG, Bergsland N, et al
    High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis.
    J Neurol Sci. 2020;418:117120.
    >> Share

    August 2020
  39. GELIBTER S, Orrico M, Moiola L, Dagna L, et al
    Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
    J Neurol Sci. 2020;418:117104.
    >> Share

  40. SHAH Z, Wasay M, Chaudhry BZ, Fredrikson S, et al
    Multiple sclerosis in Pakistan: Current status and future perspective.
    J Neurol Sci. 2020;418:117066.
    >> Share

    July 2020
  41. MINACAPELLI E, Giordano A, Falautano M, Sangalli F, et al
    Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios.
    J Neurol Sci. 2020;417:117064.
    >> Share

  42. HUGHES AJ, Patel K, Fitzgerald KC, Brown A, et al
    Reliability and validity of the multiple sclerosis resiliency scale (MSRS).
    J Neurol Sci. 2020;418:116983.
    >> Share

  43. LUCA B, Tommaso G, Bavaro DF, Laura M, et al
    Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    J Neurol Sci. 2020;416:117011.
    >> Share

    June 2020
  44. ABBOUD H, Serra A
    The pressing questions in multiple sclerosis Care in the era of COVID-19.
    J Neurol Sci. 2020;416:117005.
    >> Share

  45. PROCKL V, Nickel FT, Utz KS, Frohlich K, et al
    Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.
    J Neurol Sci. 2020;415:116973.
    >> Share

  46. WELLER D, Lorincz L, Sutter T, Reuter K, et al
    Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
    J Neurol Sci. 2020;416:116978.
    >> Share

    May 2020
  47. LAMARGUE D, Koubiyr I, Deloire M, Saubusse A, et al
    Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study.
    J Neurol Sci. 2020;415:116929.
    >> Share

  48. KIM H, Lim YM, Kim G, Lee EJ, et al
    Choroid plexus changes on magnetic resonance imaging in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neurol Sci. 2020;415:116904.
    >> Share

  49. AHMED SI, Lohana N, Javed G, Bareeqa SB, et al
    Semantic fluency and cognitive function impairment in multiple sclerosis patients.
    J Neurol Sci. 2020;415:116898.
    >> Share

    April 2020
  50. FALSAFI Z, Tafakhori A, Agah E, Mojarrad M, et al
    Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial.
    J Neurol Sci. 2020;414:116844.
    >> Share

  51. TSANTES E, Curti E, Collura F, Bazzurri V, et al
    Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2020;414:116827.
    >> Share

    March 2020
  52. CUELLO JP, Martinez Gines ML, Tejeda-Velarde A, Medina Heras S, et al
    Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis.
    J Neurol Sci. 2020;414:116811.
    >> Share

  53. RUSSO C, Cocozza S, Riccio E, Pontillo G, et al
    Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study.
    J Neurol Sci. 2020;412:116782.
    >> Share

  54. SCOTT TF, Bertha N
    The impact of multiple sclerosis relapses on worsening over the long term; insights in the treatment era.
    J Neurol Sci. 2020;413:116773.
    >> Share

  55. FUKUMOTO S, Nakamura Y, Watanabe M, Isobe N, et al
    Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116768.
    >> Share

    February 2020
  56. OUALLET JC, Radat F, Creange A, Abdellaoui M, et al
    Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116739.
    >> Share

  57. SOLARO C, Cattaneo D, Basteris A, Carpinella I, et al
    Haptic vs sensorimotor training in the treatment of upper limb dysfunction in multiple sclerosis: A multi-center, randomised controlled trial.
    J Neurol Sci. 2020;412:116743.
    >> Share

  58. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.
    >> Share

    January 2020
  59. MARTINEZ-LAPISCINA EH, Mahatanan R, Lee CH, Charoenpong P, et al
    Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis.
    J Neurol Sci. 2020;411:116668.
    >> Share

    December 2019
  60. GROMISCH ES, Foley FW
    Can semantic fluency be used as an alternative or additional measure in the abbreviated Minimal Assessment of Cognitive Function in Multiple Sclerosis (aMACFIMS)?
    J Neurol Sci. 2019;410:116640.
    >> Share

  61. DE CARVALHO JENNINGS PEREIRA W, Flauzino T, Alfieri DF, Oliveira SR, et al
    Immune-inflammatory, metabolic and hormonal biomarkers are associated with the clinical forms and disability progression in patients with multiple sclerosis: A follow-up study.
    J Neurol Sci. 2019;410:116630.
    >> Share

  62. FUJII T, Yamasaki R, Miyachi Y, Nagata S, et al
    Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis.
    J Neurol Sci. 2019;409:116619.
    >> Share

  63. CRISTIANO E, Rojas JI, Alonso R, Alvez Pinheiro A, et al
    Consensus recommendations on the management of multiple sclerosis patients in Argentina.
    J Neurol Sci. 2019;409:116609.
    >> Share

    November 2019
  64. ZANETTA C, Robotti M, Nozzolillo A, Sangalli F, et al
    Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
    J Neurol Sci. 2019;409:116603.
    >> Share

    October 2019
  65. UYGUR M, de Freitas PB, Barone DA
    Rate of force development and relaxation scaling factors are highly sensitive to detect upper extremity motor impairments in multiple sclerosis.
    J Neurol Sci. 2019;408:116500.
    >> Share

  66. CEDERBERG KLJ, Jeng B, Sasaki JE, Braley TJ, et al
    Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.
    J Neurol Sci. 2019;407:116531.
    >> Share

    September 2019
  67. SRIWASTAVA S, Yarraguntla K, Zutshi D, Basha MM, et al
    Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures.
    J Neurol Sci. 2019;406:116482.
    >> Share

  68. O'HERLIHY F, John NA, Li V, Porter B, et al
    Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithm.
    J Neurol Sci. 2019;407:116456.
    >> Share

  69. HNILICOVA P, Kantorova E, Polacek H, Grendar M, et al
    Altered hypothalamic metabolism in early multiple sclerosis - MR spectroscopy study.
    J Neurol Sci. 2019;407:116458.
    >> Share

    August 2019
  70. SA M, Nunes CC, da Silva AM, Mota P, et al
    JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results.
    J Neurol Sci. 2019;406:116426.
    >> Share

    June 2019
  71. MINAGAR A, Alexander JS
    Cervical spinal cord atrophy impact on quality of life in MS: A neuroimaging study.
    J Neurol Sci. 2019;401:101-102.
    >> Share

    February 2019
  72. KAPLAN TB, Bove R, Galetta K, Healy B, et al
    Effect of pregnancy loss on MS disease activity.
    J Neurol Sci. 2019;397:58-60.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016